AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02754362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), a proangiogenic factor which aids in tumor vessel formation.
Study NCT02532283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.
Study NCT01139346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darinaparsin
Description: dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle.
Study NCT02754362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine
Description: Vaccine of long synthetic peptides encoding T cell epitopes in tumor associated antigens.~Vaccine Consists of:~EGFRvIII peptide 100 mcg IL13Ralpha peptide 100 mcg EphA2 peptide 100 mcg Her2/neu peptide 100 mcg YKL-40 peptide 100 mcg
Study NCT01150253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L. paracasei fermented milk
Study NCT01150253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. paracasei fermented milk
Study NCT01911702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard fluidic resuscitation.
Description: Goals:~1. arterial pressure mean ≥ 65 mmHg or equal to the pre-operative~2. diuretic rhythm ≥ 1 ml / Kg / h~3. venous saturation in vena cava ≥ 70% or mixed venous saturation as Swan Ganz's catheter (SG) ≥ 65%~4. BE> - 3~5. Central Venous Pression (PVC) ≥ 8 mmHg; for patients undergoing mechanical ventilation, this limit may be raised to 12-15 mmHg.
Study NCT01911702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volemic small treatment
Description: Goals of the treatment:~1. arterial pressure mean ≥ 60 mmHg or ≥ 10% less than the preoperative values~2. diuretic rhythm ≥ 0.5 ml / kg / h~3. venous saturation in vena cava ≥ 60% or mixed venous saturation ≥ 55% by SG~4. BE> - 5~5. PVC goal not necessary~To achieve the therapeutic goals set out above will be executed a volemic fill up to values of PVC ≤ 5 mmHg or at maximum values of 2 mmHg more the incoming If after proper filling the targets aren't yet achieved, the patient will begin infusion of vasoactive drugs following the practice of department. If after 12 hours of admission the water balance will be > 10-15 ml / kg / h an infusion of furosemide should be initiated
Study NCT02754362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC as immune adjuvant
Description: Poly-ICLC is a toll like receptor 3 agonist which directly activates dendritic cells and triggers natural killer cells to kill tumor cells.
Study NCT02754362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keyhole limpet hemocyanin (KLH)
Description: Potent Immunogen used in vaccine approaches for a number of diseases including cancer, AIDS, and infectious diseases
Study NCT03643549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib and Temozolomide Phase IB
Description: In the Phase IB of the study the following dose escalation of TMZ will be performed: The first cohort of 3 patients will receive 150 mg/m2 of IMP (TMZ) for 5 days q4w. If one patient in this cohort develops a dose limiting toxicity, another cohort of 3 patients will be treated at the same dose level until 2 or more patients in the group of 3-6 develop DLT.
Study NCT03643549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib and Temozolomide Phase II
Description: The patientes will be treated with the maximum recommended starting dose of Temozolomide and Bortezomib established in the IB phase of the study
Study NCT03402074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group hypnosis
Description: 5 session of group hypnosis, each 90 minutes, to reduce subjective stress and increase relaxation. Additional auditapes of hypnosis sessions as hoemwork
Study NCT00696007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin
Description: Neoadjuvant chemotherapy (gemcitabine and cisplatin) administered before Nephroureterectomy.~Chemotherapy regimen of three cycles of gemcitabine and cisplatin, dosed over a 3 month period Each cycle would consist of gemcitabine and cisplatin on day 1, with two other doses of gemcitabine on day 8 and day 15.~Gemcitabine dosing would be 1,000 mg/m² and cisplatin would be dosed at 70 mg/m²
Study NCT00696007 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Retrospective comparison
Description: 60 retrospective historical cohort group of subjects who have undergone a radical nephroureterectomy over the past five years
Study NCT04711694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minfulness-based Intervention
Description: The proposed MBI is an adaptation from the Mindfulness Based Stress Reduction (MBSR) and Mindfulness based Cognitive Therapy (MBCT) programs to youth. This MBI consists of a total of twelve 90 minutes long sessions, the first 8 being the intervention per se and the last 4 a proposition to the transition to regular practice and a chance to better integrate mindfulness in daily life.~A theme regarding mindfulness is addressed in each session, through meditation practices and exercises. Between sessions, participants are invited to practice at home, using an application designed for this study (the MindApp), where participants can find the recorded practices. Investigators have access to participants' use of the meditation recordings and expect that these data will provide a more objective measure of the amount of home practice.
Study NCT04711694 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Minfulness-based Intervention
Description: The proposed MBI is an adaptation from the Mindfulness Based Stress Reduction (MBSR) and Mindfulness based Cognitive Therapy (MBCT) programs to youth. This MBI consists of a total of twelve 90 minutes long sessions, the first 8 being the intervention per se and the last 4 a proposition to the transition to regular practice and a chance to better integrate mindfulness in daily life.~A theme regarding mindfulness is addressed in each session, through meditation practices and exercises. Between sessions, participants are invited to practice at home, using an application designed for this study (the MindApp), where participants can find the recorded practices. Investigators have access to participants' use of the meditation recordings and expect that these data will provide a more objective measure of the amount of home practice.
Study NCT04516239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA
Description: Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. For the THA, the standard techniques proposed by the manufacturer for insertion of the stem were followed. Neck sleeve adapters and three different prosthetic neck-shaft angles (125, 135, and 145) were available to adjust leg length and femoral offset with the large-diameter head THA system.
Study NCT04516239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HR
Description: Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. In the HR group, the capsulotomy was completed circumferentially, and the gluteus tendinous insertion on the femur was released in all men, but only when needed in women, to improve femur mobilization.
Study NCT00227019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg, IV over 10 minutes every 3 weeks
Study NCT00227019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m²; IV over 10 minutes every 3 weeks
Study NCT00227019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1000 micrograms, IM injection 1-2 weeks prior to treatment and repeated every 9 weeks until last dose of pemetrexed
Study NCT00227019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folate
Description: 350 to 1000 micrograms 1 week prior to treatment and 3 weeks after last pemetrexed dose
Study NCT00227019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg; oral, twice a day at the following times: the day before, of and after each dose of pemetrexed
Study NCT00625183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenomethionine
Study NCT00625183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00625183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT00625183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00625183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT00625183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00625183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00625183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT00625183 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02797860 — intervention group
Intervention type: DRUG
Intervention: Rocuronium
Description: comparison of onset time and duration of rocuronium using Train of Four watch
Study NCT00920413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: vitamin C 500mg orally once a day
Study NCT00920413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00202098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Variable ventilation
Description: Patients will be mechanically ventilated with Variable Ventilation (3 step with increased level of variability) and traditional CMV, for a total of 4 step. Each step lasts in 60 minutes. During this period the investigators will record the gas exchange parameters and the mechanics of the respiratory system.
Study NCT02959333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAEC
Description: hAEC: human amniotic epithelial cells
Study NCT00889915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate transdermal system
Description: Not specified in protocol; determined by local standard of care.
Study NCT00889915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine dimesylate
Description: Not specified in protocol; determined by local standard of care.
Study NCT00889915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osmotic-release oral system methylphenidate (OROS MPH)
Description: Not specified in protocol; determined by local standard of care.
Study NCT00889915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mixed amphetamine salts extended release
Description: Not specified in protocol; determined by local standard of care.
Study NCT01850394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Inject tranexamic acid solution intra-articularly after fascia closure
Study NCT01850394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Study NCT01850394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiologic saline
Description: Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Study NCT04475627 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Magnetic Resonance (CMR) imaging at 1.5T
Description: Long and short axis bSSFP cines images, long and short axis tagging images and aortic cine images will be obtained. Participants will be randomised to either have cine or tagging images obtained first.
Study NCT04475627 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Magnetic Resonance (CMR) imaging at 3T
Description: Long and short axis bSSFP cines images, long and short axis tagging images and aortic cine images will be obtained. Participants will be randomised to either have cine or tagging images obtained first.
Study NCT02447471 — intervention group
Intervention type: DEVICE
Intervention: Nexfin
Description: Nexfin cuff placed on finger to measure blood pressure
Study NCT04245176 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Genetic Counseling
Description: Standard genetic counseling: Standard of care discussion
Study NCT04245176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative Genetic Counseling
Description: Quantitative genetic counseling: Discussion is guided by tables and graphs.
Study NCT02156440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SierraSil Joint Formula 14
Description: 667 mg SierraSil® hydrothermal mineral complex
Study NCT02156440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00704951 — intervention group
Intervention type: DRUG
Intervention: Posaconazole or alternative fungal treatment
Description: Dosage of Posaconazole:~Prophylactic dosing: 200mg tid (600mg/day) Treatment dosing: 400mg bid (800mg/day)
Study NCT04464408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily
Study NCT04464408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (9 tablets) by mouth twice daily for one day, followed by (4 tablets) twice daily (Maximum days of therapy is 7 days)
Study NCT03581370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 hour infusion
Description: Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 60 minutes every 8 hours.
Study NCT03581370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 hours infusion
Description: Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 4 hours every 8 hours
Study NCT01085240 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mission Possible
Description: The intervention focuses on leisure education, exercise and community re-integration.
Study NCT01085240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mission Possible
Description: The intervention focuses on leisure education, exercise and community re-integration.
Study NCT03610880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-2349 (400 mg) plus DAG181 (200 mg)
Description: Dosing period 1 (Day 1 to 7): TG-2349 400 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
Study NCT03610880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAG181 (200 mg) plus TG-2349 (400 mg)
Description: Dosing period 1 (Day 1 to 7): DAG181 200 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
Study NCT02853071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine
Study NCT02853071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard practice
Description: standard practice
Study NCT03913871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texts to support healthy eating
Description: The intervention arm will receive tailored text messages to encourage healthy eating (increase consumption, fruits, vegetables and water; and a reduce intake of sugar sweetened beverages). Participants will receive an average of 1-2 messages per day for 4 weeks.
Study NCT03913871 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Texts to support physical activity
Description: The intervention arm will receive tailored text messages to support increased minutes of physical activity per day. Participants will receive an average of 1-2 messages per day for 4 weeks.
Study NCT01234064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Embolism Graduated Pressure Stockings (by BSN-Jobst)
Description: Apply 2 to 4 hours prior to surgery. Patient will continue to wear stockings until post-op Day 10.
Study NCT01234064 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: No Graduated Compression Stockings
Description: No stockings will be applied.
Study NCT02073539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker ST104-747
Description: 760 x 2110 mm, 228 kg, Stryker Co., Kalamazoo, Michigan, US
Study NCT02073539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shinchang SB-34p
Description: , 850 x 2080 mm,Shinchang Co.,Busan,ROK
Study NCT00121290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJG-136
Description: Given IV
Study NCT00121290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00121290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02263378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ellagic acid + annona muricata
Description: pills
Study NCT02263378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ellagic acid + annona muricata
Description: pills
Study NCT01800799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baktar 800mg h.s.
Description: Antimicrobial agent (Baktar 800mg h.s.)
Study NCT01800799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg QD
Description: Anti-inflammatory agent (Celecoxib 200mg QD)
Study NCT02254356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver Flex Bare Metal Stent
Study NCT03326297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathy manual therapy
Description: Technique for the treatment of parasympathetic innervation, Techniques for the treatment of sympathetic innervation of the digestive system, Functional visceral techniques.
Study NCT03326297 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Measures to support and education to the family
Description: Pedagogical intervention in parents and health education
Study NCT00985686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEAP Project
Description: In collaboration with experts from Alberta Health Services, the University of Calgary, and Mount Royal University, the Canadian Institute of Natural and Integrative Medicine (CINIM) has created the LEAP Project, a spirituality informed e-mental health intervention, for young people with major depressive disorders (see Appendix for sample materials). It is an online, eight module, multimedia intervention delivered over eight weeks, requiring a weekly commitment of 2-3 hours. The intervention is non-denominational and avoids a focus on any religious traditions. The program aims to treat depression by guiding depressed young people through an exploration of spiritual concepts and principles.
Study NCT00985686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LEAP Project
Description: In collaboration with experts from Alberta Health Services, the University of Calgary, and Mount Royal University, the Canadian Institute of Natural and Integrative Medicine (CINIM) has created the LEAP Project, a spirituality informed e-mental health intervention, for young people with major depressive disorders (see Appendix for sample materials). It is an online, eight module, multimedia intervention delivered over eight weeks, requiring a weekly commitment of 2-3 hours. The intervention is non-denominational and avoids a focus on any religious traditions. The program aims to treat depression by guiding depressed young people through an exploration of spiritual concepts and principles.
Study NCT03134911 — intervention group
Intervention type: DRUG
Intervention: DOAC or VKA
Description: 6 months - 2 years
Study NCT03134911 — intervention group
Intervention type: DRUG
Intervention: VKA
Description: 6 months - 2 years
Study NCT01008813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adjuvanted A(H1N1)v influenza vaccine
Description: Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 \[A/California/7/2009 (H1N1)v\] (3,8 microgram) adjuvanted with AS 03A
Study NCT01008813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: non-adjuvanted A(H1N1)v influenza vaccine
Description: Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 \[A/California/7/2009 (H1N1)v\] (15 microgram)
Study NCT01468571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 50 mg po daily of spironolactone for 8 weeks. A cross-over study where each subject will receive spironolactone or placebo in a random order for 8 weeks each.
Study NCT01468571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each subject will receive placebo or spironolactone for 8 weeks. At the end of week 8, treatment arm for each subject will be blindly switched.~So if a study patient received placebo for the first 8 weeks then he/she will be switched to receive active drug (spironolactone) for the next 8 weeks.
Study NCT02780271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person education
Description: Four in-person hands-on nutrition and physical activity education classes and cooking sessions.
Study NCT01055847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam for Inhalation (AI)
Description: Aztreonam for Inhalation